Home » Archives for January 5, 2023
January 5, 2023
RECENT POSTS
ADVERTISEMENT
CNH Industrial’s straw management solution in India
CNH_Industrial_Straw_Management_Solution An innovative solution to an age-old problem. Watch our latest webisode on cnhindustrial.com London, January 5, 2023 “Agriculture has the word culture in it,” says Kavita Sah, Head of Corporate Social Responsibility at CNH Industrial India, in our latest installment in the Breaking New Ground webisode series. She goes on to explain how a huge cultural shift was required from local farmers who were
Bolsa Electrónica de Chile Upgrades to Nasdaq Marketplace Services Platform
BEC to Move Operations to the Cloud in 2024 NEW YORK and SANTIAGO, Chile, Jan. 05, 2023 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq: NDAQ) and Bolsa Electrónica de Chile (BEC) today announced an agreement through which BEC will upgrade its current on-premise Nasdaq trading technology to Nasdaq’s SaaS-based Marketplace Services
Duck Creek to acquire Imburse Payments, a modern payments platform
Strategic acquisition will add digital, out-of-the box payments capabilities to Duck Creek’s comprehensive suite of SaaS solutions for P&C and general insurers Boston, MA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies (NASDAQ: DCT) (“Duck Creek”), the intelligent solutions provider defining the future of property and casualty (P&C) insurance,
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment. Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approval SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that